Clinical Trial Update: KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for KL-A167 injection in recurrent or metastatic nasopharyngeal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• KL-A167

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Nasopharyngeal Carcinoma, Recurrent or Metastatic | Phase 2 | Status: COMPLETED